TABLE 3.

Susceptibilities of patient-derived and constructed HIV-1 integrase molecular clones

Recombinant virus	Relative change in EC50 [mean (95% CI)] compared to that for R7/3 for indicated inhibitora
	RAL	L-900,564	L-900,525	L-870,810	L-870,812	EVG
F-15	0.726 (0.294-1.791)	0.656 (0.255-1.685)	0.329* (0.133-0.811)	0.505 (0.205-1.245)	0.330* (0.129-0.848)	0.631 (0.256-1.556)
A-6	0.429 (0.174-1.057)	0.500 (0.195-1.284)	0.946 (0.384-2.333)	0.863 (0.350-2.128)	0.836 (0.325-2.146)	0.914 (0.371-2.254)
R-6	0.940 (0.381-2.317)	1.067 (0.415-2.739)	0.644 (0.261-1.589)	1.175 (0.476-2.897)	0.412 (0.160-1.058)	0.766 (0.310-1.888)
R-31	1.330 (0.54-3.281)	0.995 (0.388-2.556)	1.005 (0.407-2.477)	1.268 (0.558-2.882)	1.589 (0.591-4.268)	1.211 (0.491-2.985)
N-19	0.815 (0.271-2.450)	0.456 (0.178-1.171)	0.998 (0.388-2.562)	1.416 (0.574-3.491)	0.927 (0.361-2.380)	0.953 (0.386-2.350)
B-27	1.371 (0.556-3.381)	0.627 (0.244-1.609)	0.592 (0.240-1.459)	1.306 (0.530-3.221)	0.966 (0.376-2.481)	1.384 (0.561-3.412)
B-28	0.724 (0.294-1.786)	0.767 (0.286-2.062)	0.766 (0.310-1.888)	0.973 (0.394-2.399)	0.673 (0.250-1.808)	0.778 (0.316-1.919)
G-8	0.596 (0.242-1.469)	0.425 (0.165-1.091)	0.286** (0.116-0.706)	0.488 (0.198-1.202)	0.515 (0.201-1.323)	0.525 (0.213-1.294)
G-4	0.994 (0.383-2.328)	0.565 (0.220-1.451)	0.847 (0.344-2.089)	1.300 (0.527-3.206)	0.643 (0.250-1.651)	1.135 (0.460-2.799)
K-2	0.955 (0.387-2.355)	0.448 (0.167-1.203)	0.394* (0.160-0.971)	0.468 (0.182-1.201)	0.461 (0.180-1.185)	0.746 (0.303-1.841)
T97A	1.879 (0.625-5.652)	0.865 (0.276-2.709)	2.000 (0.665-6.015)	6.067*** (2.017-18.249)	3.767* (1.203-11.800)	2.884 (0.959-8.674)
N155H	2.812* (1.140-6.934)	4.295** (1.672-11.032)	0.780 (0.285-2.133)	12.647*** (5.129-31.189)	2.692 (0.945-7.669)	18.197*** (7.379-44.875)

^aP value determined by Wald test of ANOVA. *, P < 0.05; **, P < 0.01; ***, P ≤ 0.001. CI, confidence interval.